Raphael U. Mohr
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Hepatitis C virus research
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
- Hepatology 31
- Hepatocellular Carcinoma Treatment and Prognosis 22
- Liver Disease and Transplantation 5
- Epidemiology 22
- Liver Disease Diagnosis and Treatment 13
- Neuroendocrine Tumor Research Advances 8
- Co-authors
- Frank Tacke (31 shared papers)Christoph Roderburg (29 shared papers)Jürgen Kurt Rockstroh (9 shared papers)Ulrich Spengler (7 shared papers)Christian P. Strassburg (9 shared papers)Tom Luedde (16 shared papers)Jonel Trebicka (8 shared papers)Münevver Demir (15 shared papers)
In The Last Decade
Raphael U. Mohr
71 papers receiving 1.7k citations
Raphael U. Mohr's Hit Papers
Peers
Comparison fields: 5 of 78
- Hepatology 777
- Oncology 330
- Epidemiology 236
- Cancer Research 84
- Immunology 103
Countries citing papers authored by Raphael U. Mohr
This map shows the geographic impact of Raphael U. Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael U. Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael U. Mohr more than expected).
Fields of papers citing papers by Raphael U. Mohr
This network shows the impact of papers produced by Raphael U. Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael U. Mohr. The network helps show where Raphael U. Mohr may publish in the future.
Co-authors
The 25 scholars most cited alongside Raphael U. Mohr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Hit paper breakdown → | 2023 | 528 |
| 2 | 2019 | 122 | |
| 3 | 2019 | 66 | |
| 4 | 2014 | 54 | |
| 5 | 2021 | 51 | |
| 6 | 2023 | 49 | |
| 7 | 2021 | 42 | |
| 8 | 2015 | 39 | |
| 9 | 2023 | 35 | |
| 10 | 2020 | 34 | |
| 11 | 2018 | 31 | |
| 12 | 2023 | 30 | |
| 13 | 2022 | 29 | |
| 14 | 2024 | 29 | |
| 15 | 2020 | 27 | |
| 16 | 2021 | 26 | |
| 17 | 2021 | 24 | |
| 18 | 2020 | 23 | |
| 19 | 2021 | 23 | |
| 20 | 2022 | 20 |
About Raphael U. Mohr
Raphael U. Mohr is a scholar working on Hepatology, Epidemiology, Oncology, Surgery and Immunology, having authored 76 papers that have together received 1.7k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Liver Disease Diagnosis and Treatment (13 papers), Cancer Immunotherapy and Biomarkers (10 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), Neuroendocrine Tumor Research Advances (8 papers), Liver Disease and Transplantation (5 papers), MicroRNA in disease regulation (4 papers) and HIV-related health complications and treatments (2 papers). The work is most often cited by research in Hepatology (777 citations), Oncology (330 citations), Epidemiology (236 citations), Cancer Research (84 citations) and Immunology (103 citations). Raphael U. Mohr has collaborated with scholars based in Germany, Denmark and Spain. Frequent co-authors include Frank Tacke, Christoph Roderburg, Jürgen Kurt Rockstroh, Ulrich Spengler, Christian P. Strassburg, Tom Luedde, Jonel Trebicka, Münevver Demir, Maria Angeles Gonzalez-Carmona and Annabelle Vogt. Their work appears in journals such as Liver International, PLoS ONE, Cancers, International Journal of Molecular Sciences and JHEP Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.